Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart MJ.
Loibl S, et al. Among authors: preger l.
Eur J Cancer. 2023 Jan;178:23-33. doi: 10.1016/j.ejca.2022.10.003. Epub 2022 Oct 18.
Eur J Cancer. 2023.
PMID: 36379186
Free PMC article.
Clinical Trial.